News Column

New Major Medical Marijuana Market Could Be a Boon for Nuvilex

Jun 20 2013 12:00AM

Marketwire

Tracker

BALTIMORE, MD -- (Marketwired) -- 06/20/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, reports that the a brand new market in the medical marijuana industry could have a great impact on Nuvilex Inc. (OTCQB: NVLX). The Company is an international firm engaged in using its live-cell encapsulation technology as part of treatments for pancreatic and other cancers along with the development of therapies based on components of medical marijuana for the treatment of oncology patients.

In recent weeks, an ever-increasingly vocal group of medical marijuana proponents has brought a new idea to the forefront: medical marijuana use for pets.

According to the American Pet Products Association (APPA), pet owners spend around $25 billion annually on pet health care with $15 billion alone going toward various veterinary services. In fact, according to the Veterinary Pet Insurance Co, 70% of pet owners polled said that they would spend whatever it would take to save a pet's life.

The increasingly common diagnosis of cancer and other serious diseases in pets has prompted a number of pet owners that use medical marijuana to give Rex or Spot marijuana to treat his illnesses and increase the quality of life. As the proliferation of medical marijuana research and product development occurs across the U.S., it is natural to assume that the clinical research will migrate to pets as well, which could be a big benefit to Nuvilex.

Since the Company aims to be a leader in medical marijuana research and product development in the oncology arena, Nuvilex could elect to enter into animal studies along these lines as well as into human trials, which could potentially increase its market opportunity by billions of dollars. Nuvilex already has a track record of engaging in canine and human oncology trials with its live-cell encapsulation-based cancer treatments for mammary and pancreatic cancer, respectively. The possibility that the cannabidiol (CBD)-based cancer treatments planned for development by the Company's subsidiary, Medical Marijuana Sciences, Inc., if combined with its live-cell encapsulation-based therapies, can be used for oncology treatments for pets as well as for humans, is clearly exciting.

A copy of this article as well as other articles and Nuvilex reports and disclaimers can be accessed by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.



Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters